Development of pH-responsive chitosan/heparin nanoparticles for stomach-specific anti-Helicobacter pylori therapy

Lin, Yu Hsin; Chang, Chiung Hung; Wu, Yu Shiun; Hsu, Yu-Chin; Chiou, Shu Fen; Chen, Yi Jen

doi:10.1016/j.biomaterials.2009.02.036

Cited by 156 publications

(105 citation statements)

References 50 publications

Supporting

Mentioning

103

Contrasting

Order By: Relevance

“…In a recently published article, researchers have utilised negatively charged heparin, a well-known anticoagulant, to produce pH-responsive NPs by ionic gelation with positively charged CS (97). Heparin has been reported to promote gastric ulcer healing by mucosal regeneration, proliferation and angiogenesis (98).…”

Section: Chitosan-heparinmentioning

confidence: 99%

“…Hence, this nanoparticulate system was expected to protect the encapsulated drug from gastric acids, adhere to the gastric mucosa, penetrate through the mucosa and act on the Helicobacter pylori infection by releasing the drug due to difference in pH. The formulation showed that the positively charged NPs interacted with the negatively charged sites and opened the tight cellular junctions and was effective against the local H. pylori infection (97).…”

Section: Chitosan-heparinmentioning

confidence: 99%

See 1 more Smart Citation

Recent Advancement of Chitosan-Based Nanoparticles for Oral Controlled Delivery of Insulin and Other Therapeutic Agents

2010

View full text Add to dashboard Cite

Abstract. Nanoparticles composed of naturally occurring biodegradable polymers have emerged as potential carriers of various therapeutic agents for controlled drug delivery through the oral route. Chitosan, a cationic polysaccharide, is one of such biodegradable polymers, which has been extensively exploited for the preparation of nanoparticles for oral controlled delivery of several therapeutic agents. In recent years, the area of focus has shifted from chitosan to chitosan derivatized polymers for the preparation of oral nanoparticles due to its vastly improved properties, such as better drug retention capability, improved permeation, enhanced mucoadhesion and sustained release of therapeutic agents. Chitosan derivatized polymers are primarily the quaternized chitosan derivatives, chitosan cyclodextrin complexes, thiolated chitosan, pegylated chitosan and chitosan combined with other peptides. The current review focuses on the recent advancements in the field of oral controlled release via chitosan nanoparticles and discusses about its in vitro and in vivo implications.

show abstract

Section: Chitosan-heparinmentioning

confidence: 99%

Section: Chitosan-heparinmentioning

confidence: 99%

Recent Advancement of Chitosan-Based Nanoparticles for Oral Controlled Delivery of Insulin and Other Therapeutic Agents

2010

View full text Add to dashboard Cite

show abstract

“…Incorporation of protein and peptide into polymeric nanoparticles and microparticles has gained a lot of interest in the last two decades to improve their oral bioavailability and stability (2)(3)(4)(5). Chitosan is one of the polymers which have gained a lot of attention in nanoparticulate drug delivery system of protein and peptide (5)(6)(7)(8)(9).…”

Section: Introductionmentioning

confidence: 99%

Serratiopeptidase Loaded Chitosan Nanoparticles by Polyelectrolyte Complexation: In Vitro and In Vivo Evaluation

2014

View full text Add to dashboard Cite

Abstract. The aim of the present study was to formulate serratiopeptidase (SER)-loaded chitosan (CS) nanoparticles for oral delivery. SER is a proteolytic enzyme which is very sensitive to change in temperature and pH. SER-loaded CS nanoparticles were fabricated by ionic gelation method using tripolyphosphate (TPP). Nanoparticles were characterized for its particle size, morphology, entrapment efficiency, loading efficiency, percent recovery, and in vitro dissolution study. SER-CS nanoparticles had a particle size in the range of 400-600 nm with polydispersity index below 0.5. SER association was up to 80 ±4.2%. SER loading and CS/TPP mass ratio were the primary parameters having direct influence on SER-CS nanoparticles. SER-CS nanoparticles were freeze dried using trehalose (20%) as a cryoprotectant. In vitro dissolution showed initial burst followed by sustained release up to 24 h. In vivo antiinflammatory activity was carried out in rat paw edema model. In vivo anti-inflammatory activity in rat paw edema showed prolonged anti-inflammatory effect up to 32 h relative to plain SER.

show abstract

“…Chitosan nano-particles maintain their stability through the GI track due to electrostatic interactions. However, on reaching at pH 7.5 the chitosan becomes unstable due to the deprotanation and ultimately collapses, releasing the drug to the target site i.e., ileum (Lin et al, 2009). Therefore, anti-MAP therapy can be designed wherein the anti-MAP drug can be loaded on chitosan nanoparticles for specific delivery of drug to the target site of infection.…”

Section: Nanotechnology Based Drug Delivery Approaches For Mapmentioning

confidence: 99%

Nanotechnology Based Therapeutics, Drug Delivery Mechanisms and Vaccination approaches for Countering Mycobacterium avium subspecies paratuberculosis (MAP) Associated Diseases

Stephen¹,

Jain²,

Dhama³

et al. 2015

Asian J. of Animal and Veterinary Advances

View full text Add to dashboard Cite

Johne's Disease (JD) is a contagious fatal granulomatous enteritis, known to affect ruminants and is caused by the acid-fast Mycobacterium avium subspecies paratuberculosis (MAP). The bacterium has also been linked to Crohn's Disease (CD) in humans. Treatment options are scarce with culling practiced in the case of Johne's Disease (JD) and administration of anti-inflammatory drugs for pain and inflammation in case of CD. In both cases antimicrobial therapy against MAP does not have the ultimate potential. The very promising, yet untapped potential of nanotechnology offers a suitable platform for developing new therapeutic strategies for diseases caused by the bacteria. Uniformity, specificity and reproducibility are some of the characteristics of nanotechnology that can be exploited for the treatment of infectious diseases. Factors like cost, efficacy, safety and bioavailability of drugs can be greatly improved when the drugs are delivered with precision and at a controlled delivery rate to the target location. Nanotechnology can help in achieving these targets. This review discusses the current scenario of available therapeutic approaches and proposes drugs targeting strategies and vaccine development methods for the treatment and prevention of MAP related diseases.

show abstract

Development of pH-responsive chitosan/heparin nanoparticles for stomach-specific anti-Helicobacter pylori therapy

Cited by 156 publications

References 50 publications

Recent Advancement of Chitosan-Based Nanoparticles for Oral Controlled Delivery of Insulin and Other Therapeutic Agents

Recent Advancement of Chitosan-Based Nanoparticles for Oral Controlled Delivery of Insulin and Other Therapeutic Agents

Serratiopeptidase Loaded Chitosan Nanoparticles by Polyelectrolyte Complexation: In Vitro and In Vivo Evaluation

Nanotechnology Based Therapeutics, Drug Delivery Mechanisms and Vaccination approaches for Countering Mycobacterium avium subspecies paratuberculosis (MAP) Associated Diseases

Contact Info

Product

Resources

About